Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components

Glioma Clinical Trial

Official title:

Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00813787
• Other study ID #: CNS-24534
• Status: Recruiting
• Phase: N/A
• First received: December 19, 2008
• Last updated: October 1, 2014
• Start date: February 2009
• Est. completion date: April 2015

Study information

• Verified date: October 2014
• Source: AHS Cancer Control Alberta
• Contact: Keith Wachowicz, PhD
• Phone: (780) 989-4334
• Email: keithwac[@]cancerboard.ab.ca
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

Description:

Existing methods of contouring tumours for radiation therapy involve manual interpretations of qualitative diagnostic images. These methods, being qualitative, do not offer a consistent and reproducible platform for contouring, making it difficult to evaluate the effects of contouring choices on treatment outcome. T2 component analysis in MRI has the potential to offer a quantitive basis for identifying tumor tissue- this potential is investigated in this pilot study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eighteen years of age or older

• Clinical subjects must have not yet begun radiation therapy

• Must have signed our study-specific consent form

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Glioma

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
AHS Cancer Control Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	T2 characteristics of glioma tissue versus normal		Before radiotherapy treatment begins	No